SENO MEDICAL INSTRUMENTS

OPTO-ACOUSTIC SYSTEMSFOR MEDICAL IMAGING AND TOMOGRAPHY

Alexander A. Oraevsky, Ph.D.

Chief Scientific Officer, Seno Medical Instruments

OPTO-ACOUSTIC IMAGING TECHNOLOGY

Disruptive Technology for Unmet NeedsMultibillion Dollar MarketPlatform for Multiple Follow-on

ApplicationsScience Validated Intellectual Property Protected GloballyExperienced Medical Device Management

TeamSeeking Investment, Strategic Partners

and Licensing Opportunities

OA is a Natural Fusion of Optical Imaging (that provides high contrast) and Acoustic Imaging (that provides high resolution). OA allows to see under the skin in the depth of tissue based on detection of ultrasound waves generated through absorption of light

Opto-Acoustic Imaging is Disruptive Technology:New medical information - maps of blood

distribution in tissues and its oxygen saturation

First new functional imaging technology in 30 years: no contrast agents or ionizing radiation

WHAT IS OPTO-ACOUSTIC IMAGING ?

micro-vasculatureMouse organs

VALIDATION OF SCIENCEPRE-CLINICAL IMAGING IN ANIMALS: BRIDGE TO

CLINIC

blood vessels

>$10M in US Government funding; >$30M for academic research worldwide

CancerCardiovascu

larIntravascula

r

StrokeBrain

Trauma

Other Blood Related

Applications

Diagnostic Imaging

Image - Guided Biopsy

Monitoring of Drug Efficacy

Monitoring of Treatment

Molecular and Functional Imaging

PLATFORM TECHNOLOGY UTILIZING LIGHT AND SOUND TO MAP AND CHARACTERIZE BLOOD IN

TISSUES AND IN ANGIOGENESIS-RELATED MICROVASCULATURE

~$40 B

~$10 B

~$35 B

~$10 B

LOUIS combines optics and acoustics to significantly improve accuracy of cancer detection and noninvasive diagnosis

ENTRY MARKET: BREAST CANCER

LOUIS™ IMAGINGPROVIDES FUNCTIONAL INFORMATION ON BLOOD

DISTRIBUTION IN ADDITION TO TISSUE STRUCTURE

OPTO-ACOUSTICS VERSUS CURRENT STANDARD OF BREAST IMAGING*

KeyProperties

Gold Standard(X-ray mammo)

LOUIS™(US+OA)

SignificantBenefits

Morphology and function

Only morphology

YesBoth

High sensitivityand specificity

Negative Predictive Value

70%/30%50-70 y.o. / <40 y.o.

98% Lower Rate of Missed Cancer

PositivePredictive Value

60%/20%50-70 y.o. / <40 y.o.

82% Reduces False Positives

PatientSafety

Carcinogenic radiation

SafeLight

No harmto patients

PatientComfort

Pain of compression

Nocompression

Patientacceptance

*References:Geller BM. Vacek PM. Skelly J. Harvey SC. The use of additional imaging increased specificity and decreased sensitivity in screening mammography. Journal Clinical Epidemiology. 58(9):942-50. Sep 2005. Quing Z. Cronin EB. Currier AA. Vine HS. Huang M. Chen N. Xu C. Benign versus Malignant Breast Masses: Optical Differentiation with US-guided Optical Imaging Reconstruction. Radiology. 237: 57-66. Oct 2005.

Issued Patents5,840,023 – The Core (umbrella) Opto-Acoustic Imaging

Patent6,309,352* – Treatment and Monitoring in Real-Time6,498,942* – Distinguishing Malignant vs. Benign

Tumors

Allowed Patents 10 / 764,213 – Molecular Imaging Using Nanoparticles

Published Patents PCT / US06 / 02186 – Treatment Using Nanoparticles

Pending Patents 11 / 656,103 – Methods of Quantitative Tomography

* Licensed from the University of Texas Medical Branch

Intellectual Property Protection

BEST-OF-BREED MANAGEMENT TEAM: KEY INDUSTRY EXPERIENCE and INFLUENCE

Janet Campbell – Chairman & CEO Co-Founder of Seno Medical Instruments, Inc.President & COO of InforMedix, Inc.

Alexander Oraevsky – Chief Scientific Officer Inventor of opto-acoustic tomographyVice President of R&D, Fairway Medical

Technologies. Ron Branstetter – President & COO

Co-Founder of Seno Medical Instruments, Inc.President & COO of Colin Medical Instruments,

Inc. William Keane - Chief Medical Officer

Former Head of Merck & Co., Clinical Affairs and R&D

SCIENTIFIC ADVISORY COMMITTEESeasoned Team of world class experts

Robert I. Kramer, M.D. – Susan G. Komen Advisory Board Founding Member

Charles Coltman, M.D. – Co-Founder of Cancer Therapy Research Center

Lester M. Crawford, D.V.M. – Former Head of the FDA

John W. Holaday, Ph.D. – Biotech entrepreneur; Among the 500 most cited scientists in the world

Patricia E. Sacks, M.D. – Director of the largest radiology practice in LA.

Tom Budinger, M.D., Ph.D. – Former president of Molecular Imaging Society; Leading expert in the field of biomedical imaging.

Walt Robb, Ph.D. – Founder of GE Medical Systems. Recipient of Medal of Technology the highest national honor for technological accomplishments from President Clinton.

FINANCIAL PROJECTIONS & KEY METRICS

Latest Seno Financial Projections

Financials * ($) 2009 2010 2011 2012 2013

Revenues 0 0 11,571 32,365 69,470

Expenditures 2,555 7,774 10,831 21,959 40,509

Net (2,555) (7,774) 740 10,406 28,952

*(In Thousands (000) USD)

THE OPPORTUNITY State of our Technology - validated through

Multimillion dollar grant fundingResearch and publications by academia worldwideLicensed our first commercial product for small animal imaging to Visual Sonics, worldwide leader in preclinical imaging research

IP protected globally and vetted for “freedom to operate”

Technology AdvantagesFirst new functional imaging technology in decadesProvides high contrast, high resolution, real-time

informationProvides structural and functional information for

detecting, diagnosing and monitoring disease stateOpportunity

Looking for $3M in Bridge and 7.75 M in series B financing

Strategic partnerships for a variety of applicationsExit strategy – acquisition or IPO in 3 years